Earnings call transcript: Syrma SGS beats Q2 2026 estimates but shares fall

Syrma SGS reported Q2 FY2027 revenue of INR 2,000 crore, up 73% year on year, and net profit of INR 124 crore, up 87%; first-half revenue rose 71% to INR 3,603 crore. Management raised full-year revenue growth guidance to 40%-45% from 35%-45%, targeting about INR 7,000 crore, but cited supply constraints and margin pressure, with H1 EBITDA margin at 9.9% versus 10.1% a year earlier. Shares fell 4.34% to INR 1,554.8, indicating a negative market reaction despite the earnings growth and guidance increase.

Analysis

The headline growth is less clean than it looks: management attributes roughly 3–5% of quarterly sales to input-cost pass-through, which lifts reported revenue without adding equivalent value or margin. More importantly, the supply constraint creates a two-sided utilization risk: Syrma can hold inventory and still miss shipments if a customer lacks one critical component. Stable working-capital days are reassuring, but do not eliminate cash tied up in strategic stock as the business scales.

The order-book mismatch is not automatically evidence of weakening demand—rolling forecasts convert to purchase orders late—but it does reduce visibility. Treat the $250 million framework and management’s long-range growth targets as pipeline, not contracted revenue, until conversion and shipment cadence are observable. Near term, front-loaded demand and supply bottlenecks make the second-half trajectory vulnerable to both a volume normalization and mix-related margin slippage.

Over 6–18 months, PCB capacity could improve mix, but the investment is large relative to the company’s current execution base; approvals, utilization, customer qualification, and delayed incentives are the real underwriting variables. Management’s projected margins and returns are targets, not established economics. The market’s negative reaction may be a useful reset after strong expectations, but without verified valuation and trading-volume data, it is not by itself a short signal. Indian EMS peers such as Dixon Technologies and Kaynes Technology may also face component bottlenecks, so a sector pair is not clean without relative valuation and supply exposure data.

Key Decisions for Investors

• Do not chase the earnings beat immediately; wait for the next one or two quarters to confirm shipment conversion, organic volume growth net of pass-through, and EBITDA margin stabilization.
• Keep Syrma on a catalyst watch rather than initiate an outright short: reassess if guidance is cut, working-capital days rise materially from the stated 60–65-day operating range, or margin guidance falls below 10%.
• For a potential long, require evidence that PCB trials and customer approvals stay on schedule, followed by disclosed utilization and realized margins; treat subsidy receipts as delayed cash flows, not current earnings support.
• Monitor inventory coverage and customer shipment schedules alongside order-book disclosures. A widening gap between reported sales momentum and order conversion, or repeated delivery slippage, would falsify the thesis that supply constraints are temporary rather than a cap on growth.